Literature DB >> 26126093

The Authors Reply.

Edwin M Spithoven1, Ron T Gansevoort1.   

Abstract

Mesh：

Year:  2015        PMID： 26126093     DOI： 10.1038/ki.2015.92

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  4 in total

1.  Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

2.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

3.  Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD.

Authors:  Laura Rodriguez-Osorio; Maria Vanessa Perez-Gomez; Alberto Ortiz
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

4.  Changing referral characteristics of patients with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Kim McFann; Berenice Reed; Xiang-Dong Yan; Robert W Schrier
Journal:  Am J Med       Date:  2013-07-03       Impact factor: 4.965
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.